

## Bulletin from the Extraordinary General Meeting in LIDDS AB (publ) on the 9 January 2023

**The Extraordinary General Meeting in LIDDS AB (publ) (“LIDDS” or the “Company”) was held on 9 January 2023 and in particular the following decisions were resolved.**

### **Approval of the resolution by the Board of Directors to issue new shares with preferential rights for the shareholders**

The Extraordinary General Meeting resolved to approve the Board of Directors' resolution of 16 December 2022, to increase the Company's share capital by a maximum amount of SEK 1,841,208.92 through the issue of a maximum number of 34,739,791 shares.

The shareholders of the Company shall have preferential rights to subscribe for the new shares in relation to the number of shares previously held, whereby one existing share entitles to subscribe for one new share. The record date for determining which shareholders shall be entitled to subscribe for new shares on a preferential basis shall be 18 January 2023. The subscription price is SEK 1.40 per share which in the case of full subscription provides issuing proceeds of up to approximately 48.6 MSEK.

Subscription for new shares based on subscription rights shall be made through payment in cash during the period from 23 January 2023 until and including 6 February 2023. Subscription without subscription rights shall be made through notice on special application form during the period from 23 January 2023 until and including 6 February 2023.

### **Authorisation for the Board of Directors to resolve on a new issue of shares in case of oversubscription (over-allotment option)**

The Extraordinary General Meeting resolved to authorise the Board of Directors to, on one occasion, not later than 28 February 2023, decide on a new issue of shares in the event of oversubscription in the rights issue. The Company's share capital can be increased by a maximum of SEK 567,857.105 through a new issue of not more than 10,714,285 shares. The new shares shall be subscribed for with deviation from the shareholders' preferential rights. The purpose of the authorisation and the reason for the deviation from the shareholders' preferential rights is the possibility of bringing additional capital to the Company (so-called over-allotment option).

### **Authorisation for the Board of Directors to resolve on a new issue of shares for compensation to guarantors**

The Extraordinary General Meeting resolved to authorise the Board of Directors to, on one occasion, not later than 28 February 2023, resolve on a new issue of shares to guarantors in the rights issue. The Company's share capital shall be increased by a maximum of SEK 189,891.421 through a new issue of a not more than 3,582,857 shares at a subscription price of SEK 1.40 per share. The new shares shall be subscribed for with deviation from the shareholders' preferential rights. The purpose of the authorisation and the reason for the deviation from the shareholders' preferential rights is to pay compensation to such guarantors in the rights issue who have chosen to receive the guarantee compensation in the form of newly issued shares.

Notice and complete proposals are available on the company's website: <https://liddspharma.com/en/corporate-governance/>

**For additional information, please contact**

---

Anders Månsson, CEO  
Phone: +46 (0)70 860 47 38  
E-mail: [anders.mansson@liddspharma.com](mailto:anders.mansson@liddspharma.com)

Jenni Björnulfson, CFO  
Phone: +46 (0)70 855 38 05  
E-mail: [jenni.bjornulfson@liddspharma.com](mailto:jenni.bjornulfson@liddspharma.com)

LIDDS' Certified Adviser is Redeye AB

**LIDDS in brief:**

---

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and can solve problems within many indication areas, mainly within oncology. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage clinical phase, and projects about to enter clinical development. The company is listed on Nasdaq First North Growth Market.

**Attachments**

---

**Bulletin from the Extraordinary General Meeting in LIDDS AB (publ) on the 9 January 2023**